Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thibault Gauduchon

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Opinion in Oncology|March 12, 2025
Therapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinomaThibault Gauduchon, Eve Marie Neidhardt, Jerome Fayette
Future Oncology (London, England)|July 10, 2025
Selpercatinib in the treatment of thyroid cancerThibault Gauduchon, Romain Varnier, Philippe A Cassier
Bulletin Du Cancer|November 6, 2024
Hélène Lasolle, Françoise Borson-Chazot, Thibault Gauduchon, et al.
Frontiers in Oncology|November 28, 2022
Expanding the molecular spectrum of tenosynovial giant cell tumorsThibault Gauduchon, Helene Vanacker, Daniel Pissaloux, et al.
Oral Oncology|May 13, 2026
Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trialThibault Gauduchon, Laurence Digue, Céline Ferlay, et al.
Gynecologic Oncology|April 27, 2023
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patientsThibault Gauduchon, Maria Kfoury, Domenica Lorusso, et al.
Communications Medicine|July 6, 2026
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancerChristoph Schultheiß, Brenda Besemer, Edith Willscher, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Opinion in Oncology|March 12, 2025
Therapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinomaThibault Gauduchon, Eve Marie Neidhardt, Jerome Fayette
Future Oncology (London, England)|July 10, 2025
Selpercatinib in the treatment of thyroid cancerThibault Gauduchon, Romain Varnier, Philippe A Cassier
Bulletin Du Cancer|November 6, 2024
Hélène Lasolle, Françoise Borson-Chazot, Thibault Gauduchon, et al.
Frontiers in Oncology|November 28, 2022
Expanding the molecular spectrum of tenosynovial giant cell tumorsThibault Gauduchon, Helene Vanacker, Daniel Pissaloux, et al.
Oral Oncology|May 13, 2026
Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trialThibault Gauduchon, Laurence Digue, Céline Ferlay, et al.
Gynecologic Oncology|April 27, 2023
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patientsThibault Gauduchon, Maria Kfoury, Domenica Lorusso, et al.
Communications Medicine|July 6, 2026
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancerChristoph Schultheiß, Brenda Besemer, Edith Willscher, et al.
Pageof 1